Malta - Inggris - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - salmeterol xinafoate, fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg fluticasone propionate 125 µg - drugs for obstructive airway diseases

Malta - Inggris - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - salmeterol xinafoate, fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg fluticasone propionate 250 µg - drugs for obstructive airway diseases

Amerika Serikat - Inggris - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug

Amerika Serikat - Inggris - NLM (National Library of Medicine)

glaxosmithkline llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug

Amerika Serikat - Inggris - NLM (National Library of Medicine)

glaxo operations uk ltd - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol;   - powder for inhalation - 50 mcg/dose - active: salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol   excipient: lactose monohydrate - serevent is indicated for long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma) in adults and children who are receiving inhaled or oral corticosteroids. serevent should be used only as an adjunct to corticosteroids in the management of asthma. serevent should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

Yunani - Yunani - Εθνικός Οργανισμός Φαρμάκων

glaxosmithkline ΜΟΝΟΠΡΟΣΩΠΗ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ Δ.Τ. glaxosmithkline ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.Β.Ε. Λεωφ. Κηφισίας 266,, 152 32 152 32, Χαλάνδρι 210-6882100 - salmeterol xinafoate - inh.sol.p (ΔΙΑΛΥΜΑ ΓΙΑ ΕΙΣΠΝΟΗ ΥΠΟ ΠΙΕΣΗ) - 25 mcg/dose - salmeterol xinafoate 36,3mcg - salmeterol

Belgia - Prancis - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - xinafoate de salmétérol 0,073 mg - eq. salmétérol 0,05 mg; propionate de fluticasone 0,1 mg - poudre pour inhalation en récipient unidose - 50 µg/dose - 100 µg/dose - xinafoate de salmétérol 0.073 mg; propionate de fluticasone 0.1 mg - salmeterol and fluticasone

Belgia - Belanda - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - salmeterolxinafoaat 0,073 mg - eq. salmeterol 0,05 mg; fluticasonpropionaat 0,25 mg - inhalatiepoeder, voorverdeeld - 50 µg/dose - 250 µg/dose - salmeterolxinafoaat 0.073 mg; fluticasonpropionaat 0.25 mg - salmeterol and fluticasone

Belgia - Prancis - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - xinafoate de salmétérol 0,073 mg - eq. salmétérol 0,05 mg; propionate de fluticasone 0,25 mg - poudre pour inhalation en récipient unidose - 50 µg/dose - 250 µg/dose - xinafoate de salmétérol 0.073 mg; propionate de fluticasone 0.25 mg - salmeterol and fluticasone